Last reviewed · How we verify

Metformin HCI XR — Competitive Intelligence Brief

Metformin HCI XR (Metformin HCI XR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

phase 3 Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Metformin HCI XR (Metformin HCI XR) — The University of Texas Health Science Center at San Antonio. Metformin HCl XR reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Metformin HCI XR TARGET Metformin HCI XR The University of Texas Health Science Center at San Antonio phase 3 Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
metformin and liraglutide metformin and liraglutide University Medical Centre Ljubljana marketed Biguanide + GLP-1 receptor agonist combination AMP-activated protein kinase (metformin); GLP-1 receptor (liraglutide)
metformin 0.85 twice daily for 6 months metformin 0.85 twice daily for 6 months Xiang Guang-da marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
Pioglitazone + Metformin Pioglitazone + Metformin Sun Yat-sen University marketed Thiazolidinedione + Biguanide combination PPAR-γ (pioglitazone); AMPK/mitochondrial complex I (metformin)
Dapagliflozin / metFORMIN Pill Dapagliflozin / metFORMIN Pill Tan Tock Seng Hospital marketed SGLT2 inhibitor / Biguanide combination SGLT2 (sodium-glucose cotransporter 2) / AMPK (AMP-activated protein kinase)
metformin and roflumilast metformin and roflumilast University Medical Centre Ljubljana marketed Combination therapy: biguanide and phosphodiesterase-4 inhibitor Metformin: mitochondrial glycerophosphate dehydrogenase; Roflumilast: phosphodiesterase-4 (PDE-4)
rosiglitazone-metformin rosiglitazone-metformin GlaxoSmithKline marketed Thiazolidinedione + Biguanide combination PPAR-γ (rosiglitazone component); Complex mitochondrial mechanism (metformin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

  1. AstraZeneca · 4 drugs in this class
  2. Merck Sharp & Dohme LLC · 3 drugs in this class
  3. University of Texas Southwestern Medical Center · 2 drugs in this class
  4. Mount Sinai Hospital, Canada · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Eli Lilly and Company · 2 drugs in this class
  7. University Magna Graecia · 2 drugs in this class
  8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
  9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
  10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin HCI XR — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-hci-xr. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: